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Abstract 
Colistin is considered as one of the last-resort antibiotics and reliable antimicrobial susceptibility testing is therefore 
crucial. The reference standard for AST according to EUCAST and CLSI is broth microdilution (BMD). However, BMD is 
labor intensive to perform. Commercial antimicrobial susceptibility tests derived from BMD method are available. We 
investigated the performance of four different commercial tests: Sensititre™, SensiTest™ Colistin, Micronaut MIC Strip 
Colistin and UMIC Colistin using 70 clinical isolates (half of them was deemed by VITEK2 as resistant), including isolates 
from cystic fibrosis patients and mcr-1 bearing isolates. We used two reference standards: BMD and composite MIC as 
determined by all four tests. Sensititre™ had essential agreement (EA, defined as minimum inhibitory concentration 
within ± 1 dilution) of 87% and 89% compared to BMD and composite reference standard, respectively. For SensiT-
est™, the EA’s were 93% and 90%. For UMIC, 87% and 90%, and for Micronaut, 83% and 84%. All four tests demon-
strated categorical agreement (CA) above 90%. CA for SensiTest™ and Micronaut was both 96%, UMIC 94%, and 
Sensititre™ 93%. All tests were reproducible as tested in two quality control isolates. In conclusion, in clinical isolates 
from a large referral center, the four commercial tests for determination of colistin minimum inhibitory concentrations 
showed acceptable performance.
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Introduction
Colistin is a polypeptide antibiotic that targets the outer 
membrane of Gram-negative bacteria [1]. It is considered 
as a last-resort antibiotic due to the increasing number 
of extensively drug-resistant bacteria and limited avail-
ability of new antimicrobial agents [2–5]. It is used in 
particular for treatment of infections caused by exten-
sively drug-resistant (XDR) Klebsiella pneumoniae, Pseu-
domonas aeruginosa and Acinetobacter baumanii [5]. 
The proportion of microorganisms resistant to colistin 
is still relatively low at this moment but there is concern 
that it may increase in the future [5]. In a multicenter 
study in the US, the proportion of carbapenem resistant 
K. pneumoniae that were also colistin-resistant was 17% 
[6]. Reliable antimicrobial susceptibility testing (AST) for 
colistin is thus important, in order to prevent the patients 
receiving this nephrotoxic agent when it is unlikely to be 
effective.
Routine AST’s commonly used by microbiology labo-
ratories include automated systems such as VITEK2. Yet, 
this system is not suitable for mucoid isolates that are 
often found in patients with cystic fibrosis. Other routine 
methods for colistin AST are gradient diffusion or disk 
diffusion. Yet, they are inappropriate because colistin 
molecules are large cationic molecules that diffuse poorly 
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in the diffusion-based assays [7]. Another problem with 
gradient or disk diffusion is the need to use proper plastic 
ware since colistin can bind to polystyrene and influences 
the determination of colistin MIC [8]. Clinical and Labo-
ratory Standard Institute (CLSI) and European Commit-
tee on Antimicrobial Susceptibility Testing (EUCAST) 
recommend broth microdilution (BMD) as the refer-
ence method [1]. Due to the restriction implemented by 
EUCAST and CLSI regarding AST for colistin, routine 
laboratories are now forced to introduce this laborious 
technique in their daily routine setting. Fortunately, sev-
eral companies responded to this challenge, by bringing 
an easy-to use AST for colistin based on BMD method 
to the market [9, 10]. So far only a few studies have been 
published regarding the performance of commercial 
BMD colistin. Due to the low number of colistin resistant 
isolates in some setting, testing the commercial tests may 
be difficult. The study from EUCAST development labo-
ratory included for example 75 samples and tested five 
commercial tests using isolates which originated from 
multiple sites in Europe [10] and did not include chal-
lenging isolates such as isolates originated from cystic 
fibrosis patients. Other studies used mixed isolates origi-
nated from human and veterinary samples [11] or only 
investigated one test [12].
In this study, we evaluated the performance of four 
commercially available BMD products for determina-
tion of colistin minimum inhibitory concentration (MIC) 
in comparison to the reference BMD method in isolates 
originated from a large referral center.
Materials and methods
Bacterial isolates
The microorganisms used in this study were isolated as 
part of standard care of patients admitted to Erasmus 
Medical Center University Hospital between 2009 and 
2017. The isolates originated from various anatomical 
sites such as sputum, urine, tissues and blood. They were 
stored at -80◦C and identified to species level prior to 
microdilution test by using Microflex LT mass spectrom-
eter (Bruker Daltonik GmbH, Bremen, Germany) with 
commercial database according to the manufacturer’s 
instructions. Half (n = 35) of the isolates were selected 
since they were deemed as colistin resistant by VITEK2 
(bioMérieux SA, Marcy l’Etoile France) and were cat-
egorized as such according to European Committee of 
Antibiotic Susceptibility Testing (EUCAST) breakpoint, 
i.e. MIC of > 2  μg/mL [13]. Other isolates were selected 
to enrich the species variation or selected from specific 
patient groups.
Seventy isolates were thus used in this study, and con-
sisted of 44 Enterobacterales (Escherichia coli (n = 19), 
Klebsiella pneumoniae (n = 14), Enterobacter cloacae 
complex (n = 3), Enterobacter spp. (n = 3), Proteus hau-
seri (n = 1), Citrobacter freundii (n = 1), Kluyvera georgi-
ana (n = 1), Klebsiella variicola (n = 1), and Serratia spp. 
(n = 1)), and 26 non-fermentative Gram-negatives (Pseu-
domonas aeruginosa (n = 23), Acinetobacter spp. (n = 2), 
and Achromobacter xylosoxidans (n = 1)).
Thirteen isolates originated from patients with cystic 
fibrosis, eleven P. aeruginosa, one K. variicola, and one 
A. xylosoxidans. Among the Enterobacteriales, 17 (39%) 
were phenotypically positive for extended spectrum beta-
lactamase (ESBL). ESBL was phenotypically detected 
using Combination Disc Test, i.e. disk diffusion by apply-
ing cefotaxime or ceftazidime alone, and in combination 
with clavulanic acid. ESBL was detected if the inhibition 
zone diameter was  ≥ 5  mm larger with clavulanic acid 
than without.
The collection was analyzed for the presence of mcr-1 
gene using PCR as described before [3], which was pre-
sent in seven of the included isolates (five E. coli, one K. 
georgiana, and one K. pneumoniae).
Further, we included quality control (QC) strains E. coli 
ATCC 25922 (colistin susceptible), E. coli NCTC13846 
(mcr-1 positive), and P. aeruginosa ATCC 27853 (colistin 
susceptible).
Reference standard
Reference MICs for colistin were determined using man-
ual BMD, performed according to ISO standard 20776-1 
[14]. MIC panels were prepared with pure colistin sulfate 
powder (Sigma–Aldrich, Illkirch, France) with two-fold 
dilutions in the range of 0.125 to 64  μg/mL in cation-
adjusted MH broth (Becton–Dickinson, Sparks, MD, 
USA) in polystyrene plates (Greiner). Results were read 
after incubation in aerobic atmosphere at 35 ± 1  °C for 
18 h.
BMD is a reference standard that is chosen by stand-
ardization institutes, but it might also prone to error 
as inherent variability can exist [15] and in this study 
because BMD uses polystyrene plastic. Therefore, to 
get an idea whether the performance of commercial 
MIC tests was robust, we created a composite reference 
standard using the MIC’s determined by the four com-
mercial BMD tests. This approach could be considered 
as an alternative and/or complementary to the standard 
approach using BMD.
To investigate the robustness of the performance of 
the tests,. The MIC’s of the microorganism using this 
method are determined as follows. First, the range, i.e. 
the lowest and the highest MIC value from the four 
commercial tests was determined. When the difference 
between these two values was an even-fold number of 
dilutions, the middle dilution was set as the MIC of the 
microorganism. For example, when the lowest MIC was 
Page 3 of 8Yusuf et al. Ann Clin Microbiol Antimicrob           (2020) 19:42  
8  µg/ml by one test, and the highest was 32  µg/ml by 
another test (twofold dilution difference), the MIC was 
set at 16 µg/ml. When the difference was uneven-fold, 
the middle two dilutions were chosen as the reference 
MIC values. For example, the lowest MIC of 8  µg/ml 
by one test, and the highest 64  µg/ml by another test 
(threefold dilution difference), the MIC was put at 
16 µg/ml and 32 µg/ml.
MIC determinations of colistin
MIC determinations for colistin were performed 
according to the manufacturers’ instructions by four 
commercially available BMD tests: YFRCOL Sensiti-
tre™, further referred to as Sensititre™ (Thermo Fisher 
Scientific, Cleveland, USA), SensiTest™ Colistin, fur-
ther referred to as SensiTest™ (at present is re-branded 
as ComASP™ Colistin, Liofilchem, Roseto degli Abru-
zzi, Italy), Micronaut MIC Strip Colistin, further 
referred to as Micronaut (Merlin Diagnostika GmbH, 
Bornheim, Germany), and UMIC Colistin, further 
referred to as UMIC (Biocentric, Bandol, France).
Sensititre™ is a 96-wells plate containing colistin 
in two-fold dilution in the range of 0.125 to 128  µg/
ml, allowing testing of eight isolates simultaneously. 
SensiTest™ has four panels, containing colistin in seven 
two-fold dilutions (0.25 to 16  µg/ml). Micronaut and 
UMIC are single isolate strips, containing freeze-dried 
colistin in 11 two-fold dilutions (0.0625 to 64 µg/ml).
One and the same suspension was prepared to 
inoculate these four systems (and the reference BMD 
method) in parallel. For Sensititre™, 10  μl of the 0.5 
McF was suspended in 11  ml Mueller–Hinton (MH) 
broth provided by the manufacturer, of which 50  μl 
was inoculated in each well. For SensiTest™, the 0.5 
McF solution was diluted 1:20 in saline, and 0.4  ml of 
this solution was added to a 3.6 ml tube of MH 2 broth 
provided by the manufacturer, and 100 µl of the mixed 
solution was dispensed into each well. For Micronaut, 
50  µl of the 0.5 McF solution was added with 11  ml 
MH broth, and 100 µl of the solution was added in each 
well. For UMIC, the 0.5 McF suspension was directly 
diluted 1:200 in one of the MH2 tubes provided with 
the kit, of which 100 μL was added in each well of the 
unitary strip.
The results were read by unaided eye after incubation in 
aerobic atmosphere at 35 ± 1 °C for 18 ± 2 h and re-read 
after another 18 ± 2 h only if no growth was seen in the 
wells. Growth was considered when turbidity was present 
at the bottom of the well. The tests were considered as 
valid only if growth in the growth control was observed, 
and if no ‘skipped well’ occurred (i.e. no growth in a well 
but growth in a well with a higher colistin concentration).
Statistical analysis
Accuracy, defined as the closeness of the result obtained 
with the commercial tests to the true value (BMD refer-
ence standard or the composite reference standard) [15] 
was determined by calculating essential agreement (EA) 
and categorical agreement (CA).
EA was defined as MIC determined by commercial 
tests that was within ± 1 dilution of the reference stand-
ard. CA was defined as total number of isolates tested 
using the commercial tests that yielded the same categor-
ical interpretation as the reference standard according to 
EUCAST Breakpoint Tables version 9.0 (susceptible ≤ 2, 
resistant > 2 µg/ml) [13]. To cope with differences in con-
centration ranges between reference standard and com-
mercial tests for the calculation of EA, the highest and 
lowest MIC concentration were considered as having 
essential agreement.
Very major error (VME) and major error (ME) pro-
portions were calculated. VME was defined as resistant 
by reference BMD, but susceptible by commercial tests 
(false susceptible). ME was defined as susceptible by ref-
erence BMD but resistant by commercial tests. EA’s and 
CA’s were also determined by testing QC isolates E. coli 
ATCC 25922 (target MIC 0.5 to 1 µg/ml, range 0.25 to 2), 
E. coli NCTC13846 (target MIC 4  µg/ml, range 2 to 8), 
and P. aeruginosa ATCC 27853 (target MIC 1 to 2 µg/ml, 
range 0.5 to 4).
The reproducibility of the commercial tests was 
assessed by testing the latter two QC isolates three and 
six times, respectively. The tests were deemed as repro-
ducible when the MIC’s were within ± onefold dilution.
Results
MIC characteristics of bacterial isolates according to BMD 
and commercial tests
The MIC distribution of the included isolates as deter-
mined by the four commercial tests are presented in 
Fig.  1. In two isolates, Sensititre™ measured a MIC 
above its upper MIC dilution limit (> 128  µg/ml) and 
in one isolate at or below its lower MIC dilution limit 
(≤ 0.125  µg/ml). SensiTest™ measured seven isolates 
above its upper dilution limit (> 16 µg/ml), and thirteen 
at or below lower level of dilution limit (≤ 0.25  µg/ml). 
By UMIC and Micronaut, with similar dilution range, 
eight and six isolates respectively were measured above 
upper dilution limit (MIC > 64 µg/ml) and no isolates had 
a MIC ≤ 0.0625  µg/ml.In more than the half of the iso-
lates, the MIC’s determined by the four commercial tests 
were either the same (n = 17, 24%), or within ± 1 dilution 
(n = 28, 40%). Two isolates had MICs above upper MIC 
dilution limits by all four tests. A difference of ± 2 dilu-
tions occurred 13 times (19%), and ± 3 or more in 10 
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isolates (14%). The maximum difference among the com-
mercial tests was 8 dilutions, in a P. aeruginosa (MICs 
in µg/ml according to Sensititre™ 4, SensiTest™ > 16, 
UMIC > 64, Micronaut MIC Strip 0.5).
The MIC could not be determined in one P. aeruginosa 
isolate by all four tests after 18 + 2 h of incubation and in 
another P. aeruginosa isolate by all tests except Sensiti-
tre™ because of lack of growth. In four isolates, a skipped 
Fig. 1 The MIC distribution of the included isolates as determined by the four commercial tests and broth microdilution reference standard
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well occurred in UMIC and Micronaut at 18 ± 2  h of 
incubation. In all cases, except for one Acinetobacter spp. 
using UMIC, MIC’s could be read after another 18 ± 2 h 
of incubation.
Performance of commercial MIC colistin tests
The commercial tests had EA’s of above 80% compared 
to BMD reference standard (Table 1), SensiTest™ showed 
the highest EA (92.8%, 65/70) and Micronaut showed the 
lowest EA (82.9%, 58/70) and the EA’s remained above 
80% when the alternative composite reference standard 
was used. Compared with Enterobacteriales, the perfor-
mance of the commercial tests on non-fermenters was 
lower; the EAs of UMIC and Micronaut were lower than 
80% (76.9%, 20/26 and 69.2% 18/26 respectively). The 
performance of commercial tests for non-fermenters was 
increased when composite reference standard was used.
All four tests demonstrated a CA above 90%, with 
SensiTest™ and Micronaut both 95.7% (67/70), UMIC 
94.3% (66/70), and Sensititre™ 92.9% (65/70) (Table  2). 
The EA’s using commercial MIC tests for colistin were 
considerably better than VITEK2.
Two isolates were consistently deemed as VME across 
the four commercial tests, a P. aeruginosa (BMD MIC 
8 µg/ml, harbouring blaVIM-1) and a K. pneumoniae (MIC 
according to BMD 16 µg/ml) (Table 3). Next to these iso-
lates, Sensititre™ showed false susceptibility (VME) in 
one Acinetobacter spp. (MIC 2; BMD MIC 4 µg/ml), and 
two E. coli’s (both MIC 2; BMD MIC 4 µg/ml and both 
were positive for extended spectrum beta-lactamases). 
SensiTest™ showed a third VME in one P. aeruginosa 
from a cystic fibrosis patient (MIC 1; BMD MIC 8  µg/
ml). Micronaut also showed a third VME in one P. aer-
uginosa (MIC 0.5; BMD MIC 64  µg/ml, isolated from a 
CF patient).
Performance of the commercial tests in cystic fibrosis 
and mcr‑1 gene harboring isolates
The EA’s of the commercial tests in the 13 isolates origi-
nating from cystic fibrosis patients were 76.9% (Sensiti-
tre™; 10/13), 92.3% (SensiTest™; 12/13), 84.6% (UMIC; 
Table 1 Essential Agreements of commercial MIC tests compared to reference standard Broth Microdilution, n (%)
a  No growth counted as disagreement
Isolates n Sensititre™ SensiTest™ colistin UMIC colistine Micronaut MIC strip–
colistin
vs. BMD vs. 
composite 
reference
vs. BMD vs. 
composite 
reference
vs. BMD vs. 
composite 
reference
vs. BMD vs. 
composite 
reference
Total 70 61 (87.1) 62 (88.6) 65 (92.8) 63 (90.0) 61 (87.1)a 62 (88.6)a 58 (82.9) 59 (84.3)
Enterobacteriales 44 39 (88.6) 38 (86.4) 42 (95.5) 40 (90.9) 41 (93.2) 38 (86.4) 40 (90.9) 38 (86.4)
 Escherichia coli 19 19 (100) 19 (100) 19 (100) 18 (94.7) 19 (100) 19 (100) 19 (100) 19 (100)
 Klebsiella pneumoniae 14 11 (78.6) 12 (85.7) 13 (92.9) 14 (100) 13 (92.9) 13 (92.9) 12 (85.7) 12 (85.7)
 Enterobacter cloacae complex 3 1 (33.3) 3 (100) 3 (100) 3 (100) 3 (100) 2 (66.7) 2 (66.7) 2 (66.7)
 Enterobacter spp. 3 3 (100) 1 (33.3) 3 (100) 1 (33.3) 3 (100) 1 (33.3) 2 (66.7) 1 (33.3)
 Proteus hauseri 1 1 (100) 1 (100) 0 (0) 1 (100) 1 (100) 0 (0) 1 (100) 0 (0)
 Citrobacter freundii 1 1 (100) 1 (100) 1 (100) 1 (100) 0 (0) 1 (100) 1 (100) 1 (100)
 Kluyvera georgiana 1 1 (100) 0 (0) 1 (100) 1 (100) 0 (0) 0 (0) 1 (100) 1 (100)
Klebsiella variicola 1 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100)
Serratia spp. 1 1 (100) 0 (0) 1 (100) 0 (0) 1 (100) 1 (100) 1 (100) 1 (100)
Non fermentative Gram-negatives 26 22 (84.6) 24 (92.3) 23 (88.5) 23 (88.5) 20 (76.9) 24 (92.3) 18 (69.2) 21 (80.8)
Pseudomonas aeruginosa 23 20 (86.9) 22 (95.7) 20 (87.0) 20 (87.0) 18 (78.6) 22 (95.7) 17 (73.9) 20 (87.0)
Acinetobacter spp. 2 2 (100) 1 (50) 2 (100) 2 (100) 1 (50)a 1 (50)a 1 (50) 1 (50)
Achromobacter xylosoxidans 1 0 (0) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 0 (0)
Table 2 Categorical Agreements of  commercial MIC tests 
compared to reference standard Broth Microdilution, n (%)
a  No growth in one isolate
Categorical 
agreement, n 
(%)
Very major 
error, n (%)
Major error, n (%)
Sensititre™ 65 (92.9) 5 (14.7) 0 (0)
SensiTest™ 67 (95.7) 3 (8.8) 0 (0)
UMIC 66 (94.3) 2 (5.9) a 1 (0) a
Micronaut 67 (95.7) 3 (8.8) 0 (0)
VITEK2 (n = 56) 47 (83.9) 3 (8.8) 6 (10.7)
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11/13), and 69.2% (Micronaut; 9/13). The CA’s were 100% 
for Sensititre™ and 92.3% for the other three tests.
All seven isolates harboring mcr-1 gene were deemed 
as resistant by the four commercial tests, except for one, 
which was tested susceptible by Sensititre™ (MIC 2  µg/
ml; BMD MIC 4 µg/ml). The MIC of one isolate accord-
ing to Sensititre™ (4 µg/ml) was two dilutions lower than 
BMD (16 µg/ml). The remaining five isolates, had a MIC 
of 4 µg/ml, which was in agreement with BMD. SensiT-
est™ and Micronaut showed essential agreement for all 
seven mcr-1 gene isolates. UMIC showed essential agree-
ment in six out of the seven isolates; in one isolate the 
MIC was two dilutions higher than BMD (8 µg/ml).
Reproducibility
All commercial tests showed 100% reproducibility. Sen-
sititre™ showed exactly the same MIC for E. coli NCTC 
13846 and for P. aeruginosa ATCC 27853 in all three and 
six reproductions respectively.
In E. coli NCTC 13846 SensiTest™, UMIC and Micro-
naut showed exactly the same MIC in two out of three 
repeats. SensiTest™ showed exactly the same MIC in five 
out of six reproductions of P. aeruginosa ATCC 27853, by 
UMIC MICs for this isolate were the same six times, and 
by Micronaut there was one doubling dilution difference 
three out of the six repeats.
Discussion
In this study we investigated the performance of four 
commercial tests to determine MIC of colistin. To the 
best of our knowledge, only a few studies have evaluated 
these tests. Our study evaluated these four tests in clini-
cal isolates. Also included were isolates from cystic fibro-
sis patients, which are often mucoid and cannot be tested 
using VITEK2.
Our results showed that the CA of the four com-
mercial tests were high, i.e. ≥ 90%. These high CA’s are 
comparable with a study from EUCAST Development 
laboratory using 75 international isolates where Sen-
sititre™, SensiTest™, UMIC and Micronaut were also 
tested [10]. The categorical disagreement in Sensititre™ 
was caused mainly by two isolates with the MIC around 
the breakpoint, where Sensititre™ showed a lower MIC 
than the reference. This tendency was also found in the 
EUCAST study [10] and can be explained by the absence 
of intermediate (‘I’) category in EUCAST and CLSI 
breakpoint tables, that is normally used as a buffer zone 
for possible technical errors.
Jayol et  al. evaluated Sensititre™ and UMIC on a col-
lection of 185 Gram-negative isolates, of which 39 were 
non-fermenters, and found VME of 3.0% and 11.3%, 
respectively [16]. In our study, we found VME of 14.7% 
for Sensititre™ and 5.9% for UMIC. The difference might 
be due to the selection of isolates. This is also the reason 
why a hard cut-off of acceptable percentages of VME’s 
and ME’s as used by standardization bodies might be 
not appropriate to be used in this specific study. In our 
study, we included many challenging isolates and it might 
increase the number of VME’s and ME’s. This emphasizes 
the need of evaluating various commercial tests using dif-
ferent isolates with various difficulties (i.e. mucoid/not 
mucoid, antimicrobial resistance profile) in several geo-
graphical regions.
The high EA between the commercial tests and BMD 
can and should be expected since they used comparable 
AST method and the difference would be merely based 
on the type of colistin and type of materials used for the 
wells. It is known that colistin binds to the polystyrene 
and efforts have been made to prevent this. Interestingly 
in our study, we found that the EA’s of the commercial 
tests when composite reference standard was used for 
non-fermenters were better than with BMD as reference 
standard. This difference was not noticed on Enterobac-
teriales. It suggests that for non-fermenters the MICs of 
Table 3 Isolates with VME or ME (by any commercial BMD test) and their corresponding MICs (µg/ml)
VME very major error, ME major error
a BMD: broth microdilution
Isolates BMD reference 
 standarda
Sensititre™ (VME 
n = 5, ME n = 0)
SensiTest™ (VME 
n = 3, ME = 0)
UMIC (VME n = 2, 
ME = 1)
Micronaut (VME 
n = 3, ME = 0)
Pseudomonas aeruginosa 0.5 0.5 ≤ 0.25 4 2
Pseudomonas aeruginosa 8 1 1 1 1
Pseudomonas aeruginosa 64 4 > 16 > 64 0,5
Pseudomonas aeruginosa 64 16 1 4 4
Acinetobacter junii 4 2 4 4 4
Escherichia coli 4 2 4 8 4
Escherichia coli 4 2 4 4 4
Klebsiella pneumoniae 16 0.25 0.5 0.25 1
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commercial tests are more equal and less comparable to 
the BMD reference test.
We also found in our study that Micronaut had a rather 
low% EA (69.2%) in isolates from cystic fibrosis patients. 
Accurate susceptibility testing of P. aeruginosa from 
cystic fibrosis patients is often challenging because the 
organisms are often mucoid and slowly growing [17]. To 
the best of our knowledge, apart for Sensititre™ [12] none 
of the published studies regarding commercial tests for 
colistin mentioned isolates from cystic fibrosis patients. 
The% EA in their study increased, from 82% after 24  h 
incubation to 95% after 48 h incubation.
Since the MICs of the resistant mcr-1 harboring isolates 
do not necessarily need to be increased, the commercial 
tests are not optimal for screening of the presence of this 
gene for the infection prevention purposes. The commer-
cial tests in this study did allow detection of the expres-
sion of these genes.
From a practical point of view, each of the different 
commercial tests may have its advantages and disadvan-
tages. Sensititre™ and Sensitest™ are designed for testing 
respectively eight and four isolates simultaneously. These 
tests may be applicable to be used for testing in a batch in 
a large laboratory. For Sensititre™, there is also a possibil-
ity for automatic inoculation and the use of an automated 
reader. The single strip tests by UMIC and Micronaut can 
be used for immediate testing without waiting for enough 
isolates to be tested simultaneously. When no MIC can 
be read after 18 ± 2 h of incubation, another incubation is 
needed. For UMIC and Micronaut, care should be taken 
that wells do not desiccate, for which a special box is 
available.
In rare occasions, skipped-well occurred in this study. 
We do not have a clear explanation to explain this phe-
nomenon. We can only speculate that pipetting error, 
contact with polystyrene plastics may cause this problem.
The strength of our study is that we also included 
challenging isolates such as isolates from cystic fibrosis 
patients. Our study adds to the body of literature where 
isolates originated from other parts of the world. The 
results of our study can be used for other labs in order 
to organize the flow of their lab regarding colistin AST. 
In our lab, due to the findings described in this study, we 
confirm the resistant VITEK2 AST results using com-
mercial colistin MIC methods.
In conclusion, the four commercial colistin MIC meth-
ods investigated in this study showed acceptable perfor-
mance when they were compared with reference BMD 
standard.
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